Drug intelligence / Profile preview

pseudosemiglabrin

Development stage
Preclinical
Lead developer
Universiti Sains Malaysia
Modality
Small Molecules
Administration
Oral
01

Overview

Pseudosemiglabrin is a natural prenylated flavone isolated from the aerial parts of *Tephrosia* species, including *Tephrosia apollinea*, *Tephrosia semiglabra*, and *Tephrosia purpurea*. It has been investigated preclinically for its potential therapeutic applications in oncology, inflammatory diseases, epilepsy, and acute pancreatitis. In breast cancer models, pseudosemiglabrin exhibits chemopreventive and antiangiogenic properties by inhibiting VEGF expression, VEGFR phosphorylation, and the Notch pathway, as well as acting as an inhibitor of aromatase and the estrogen receptor. Additionally, it has demonstrated anti-inflammatory effects through selective COX-2 inhibition and reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta), and neuroprotective/anti-epileptic properties by modulating GABAergic and glutamatergic neurotransmission.

Other names
(-)-pseudosemiglabrinpseudo semiglabrinpseudosmiglabrin
02

Targets

ERKEGFR T790M (Epidermal growth factor receptor T790M mutant)FGFR (Fibroblast growth factor receptor)FGF (Fibroblast growth factor 6)

Beyond the preview

Go deeper on pseudosemiglabrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pseudosemiglabrin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call